Continued denosumab treatment is associated with a lower risk for diabetes in adults with osteoporosis older than 65 years, found a large-scale cohort study in Taiwan. Denosumab, used in osteoporosis ...
Entera Bio Ltd. reported its financial results for Q1 2025, highlighting significant advancements in its development of oral peptide therapies, particularly EB613, an oral anabolic treatment for ...
Because there are typically no symptoms until the first fracture occurs, osteoporosis is considered a silent disease. Some call it a silent killer. Osteoporosis is a bone disease characterized by ...
FDA qualification of Total Hip BMD as a validated surrogate endpoint for novel osteoporosis drug development further bolsters Entera's July 2025 ...
JERUSALEM, July 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response ...
Osteoporosis treatment was associated with lower mortality and hospitalization rates among people older than 80 who had suffered fractures, according to a study presented at the Endocrine Society’s ...
Osteoporosis occurs when your bones progressively break down and become weaker. The disease is often described as silent because you may not notice outward symptoms until a fracture occurs. Fractured ...
New evidence suggests that the risk for fracture increases within months of low-dose prednisone, challenging the idea of a ...
Osteoporosis is characterized by an imbalance in bone renewal, where bone loss outpaces bone replacement, leading to weakened, brittle bones. Various factors contribute to osteoporosis, including ...
But new research suggests that a simple blood test may be able to predict osteoporosis risk, allowing doctors to intervene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback